| Literature DB >> 28921787 |
Makiko Nishikii-Tachibana1,2, Vedant S Pargaonkar1, Ingela Schnittger1, Francois Haddad1, Ian S Rogers1, Jennifer A Tremmel1, Paul J Wang1.
Abstract
BACKGROUND: A myocardial bridge (MB) has been associated with ventricular arrhythmia and sudden death during exercise. QT dispersion (QTd) is a measure of abnormal repolarization and may predict ventricular arrhythmia. We investigated the frequency of ventricular arrhythmias during exercise and the QTd at rest and after exercise, in patients with an MB compared to a normal cohort.Entities:
Keywords: QT dispersion; myocardial bridging; ventricular arrhythmia
Mesh:
Year: 2017 PMID: 28921787 PMCID: PMC6931813 DOI: 10.1111/anec.12492
Source DB: PubMed Journal: Ann Noninvasive Electrocardiol ISSN: 1082-720X Impact factor: 1.468
Figure 1Study population. The study patients were divided into the following groups; (1) Echo‐MB group, (2) MB group, and (3) Control group. Additionally, the patients of Echo‐MB group and MB group were divided into an NSVT group and non‐NSVT group. CA, coronary angiography; CCTA, coronary computed tomography angiography; EE, exercise echocardiography; IVUS, intravascular ultrasound; MB, myocardial bridge; NSVT, nonsustained ventricular tachycardia
Patient characteristics
| Variables | Echo‐MB group | MB group | Control | ||
|---|---|---|---|---|---|
|
|
|
|
| ||
| Age | 53.5 ± 14.4 | .009 | 47.6 ± 16.9 | .434 | 52.6 ± 13.8 |
| Male gender, | 247(48.4) | <.001 | 38(34.5) | .030 | 114 (57.6) |
| BMI | 26.1 ± 5.0 | .054 | 25.5 ± 5.8 | .090 | 26.8 ± 4.4 |
| SBP (mm Hg) | 123.0 ± 18.0 | .169 | 119.6 ± 16.6 | .614 | 122.2 ± 15.6 |
| DBP (mm Hg) | 73.4 ± 11.5 | .561 | 72.0 ± 9.2 | .450 | 72.7 ± 11.4 |
| MBP (mm Hg) | 89.9 ± 12.1 | .304 | 87.8 ± 10.2 | .467 | 89.2 ± 11.6 |
| Beta‐blocker | 83(16.3) | .507 | 18(16.4) | .420 | 27 (13.6) |
| CCB | 47(9.3) | .276 | 10(9.1) | .101 | 27 (13.6) |
| ACE‐I/ARB | 97(19.2) | .179 | 26(23.6) | .591 | 34 (17.2) |
| LVEF (%) | 62.2 ± 4.3 | .053 | 62.0 ± 4.0 | .058 | 62.9 ± 3.6 |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; CCB, calcium channel blocker; ACE‐I/ARB, angiotensin‐converting‐enzyme inhibitor/angiotensin receptor blocker; LVEF, left ventricular ejection fraction.
Statistically significant to p < .05. p values represent difference between Echo‐MB or MB group and control group.
Exercise testing, ventricular arrhythmia, and QT interval duration/dispersion results
| Variables | Echo‐MB group | MB group | Control | ||
|---|---|---|---|---|---|
|
|
|
|
| ||
| Maximum heart rate (beats/min) | 159.2 ± 19.5 | .517 | 163.2 ± 20.4 | .183 | 161.5 ± 21.4 |
| % heart rate achieved | 95.7 ± 9.9 | .146 | 94.8 ± 9.3 | .403 | 96.4 ± 9.3 |
| Peak SBP (mm Hg) | 166.1 ± 23.6 | .828 | 163.6 ± 22.6 | .116 | 163.0 ± 22.2 |
| Peak DBP (mm Hg) | 75.7 ± 14.3 | .222 | 76.2 ± 15.4 | .159 | 74.1 ± 14.0 |
| Peak MBP (mm Hg) | 105.4 ± 14.6 | .341 | 105.9 ± 14.6 | .080 | 103.7 ± 14.3 |
| PVCs, | 254 (49.8) | <.001 | 50 (45.5) | <.001 | 11 (5.6) |
| NSVTs, | 25 (4.9) | .001 | 7 (6.4) | <.001 | 0 (0) |
| Baseline | |||||
| Heart rate (bpm) | 73.3 ± 13.3 | .003 | 73.8 ± 13.8 | .06 | 76.9 ± 14.1 |
| QT max (ms) | 383.6 ± 29.7 | .213 | 382.5 ± 31.1 | .087 | 380.3 ± 26.5 |
| QT min (ms) | 356.3 ± 28.4 | .417 | 354.4 ± 29.6 | .115 | 353.0 ± 26.5 |
| QTd (ms) | 27.3 ± 8.7 | .190 | 28.2 ± 12.6 | .576 | 27.3 ± 5.6 |
| QTcd (ms) | 30.3 ± 10.1 | .350 | 31.1 ± 14.6 | .778 | 30.6 ± 7.0 |
| Postexercise | |||||
| Heart rate (bpm) | 122.2 ± 18.1 | <.001 | 123.7 ± 18.9 | .008 | 129.9 ± 20.8 |
| QT max (ms) | 312.0 ± 24.9 | .002 | 307.8 ± 26.8 | <.001 | 299.8 ± 24.4 |
| QT min (ms) | 275.5 ± 22.9 | .968 | 270.9 ± 24.8 | .021 | 271.2 ± 23.7 |
| QTd (ms) | 36.5 ± 10.2 | <.001 | 36.8 ± 11.2 | <.001 | 28.6 ± 7.2 |
| QTcd (ms) | 51.4 ± 14.5 | <.001 | 52.0 ± 16.1 | <.001 | 37.4 ± 9.1 |
bpm, beats per minute; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure.
Statistically significant to p < .05. p values represent difference between Echo‐MB or MB group and control group.
Figure 2(a) Change in QTd (ΔQTd) with exercise in each group. Patients in the Echo‐MB and MB groups both had a significant increase in their QTd from baseline to postexercise (p < .001), whereas there was no significant change in the QTd with exercise in the Control group. Error bars represent mean with a 95% confidence interval. (b). Comparison of ΔQTd between the groups. The ΔQTd was significantly greater in the Echo‐MB group compared with the Control group and in the MB group compared with the Control group (both p < .001). ΔQTd = postexercise QTd − baseline QTd
Clinical characteristics of patients with NSVT and without NSVT in the combined Echo‐MB and MB groups
| Variables | NSVT | Non‐NSVT |
|
|---|---|---|---|
| Age | 57.2 ± 12.7 | 52.2 ± 15.1 | .067 |
| Male gender, | 23 (71.9) | 262 (44.6) | .003 |
| BMI | 26.7 ± 3.6 | 26.0 ± 5.2 | .434 |
| SBP (mm Hg) | 126.4 ± 18.0 | 122.2 ± 17.7 | .183 |
| DBP (mm Hg) | 71.6 ± 8.9 | 73.2 ± 11.3 | .313 |
| MBP (mm Hg) | 89.9 ± 9.6 | 89.5 ± 11.9 | .884 |
| Βeta‐blocker | 9 (29.0) | 92 (15.7) | .076 |
| CCB | 4 (12.9) | 53 (9.0) | .517 |
| ACE‐I/ARB | 9 (29.0) | 114 (19.5) | .246 |
| LVEF (%) | 61.7 ± 4.1 | 62.2 ± 4.3 | .475 |
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure; CCB, calcium channel blocker; ACE‐I/ARB, angiotensin‐converting‐enzyme inhibitor/angiotensin receptor blocker; LVEF, left ventricular ejection fraction.
Statistically significant to p < .05.
Exercise testing and QT interval duration/dispersion results of patients with NSVT and without NSVT in the combined Echo‐MB and MB groups
| Variables | NSVT | Non‐NSVT |
|
|---|---|---|---|
| Maximum heart rate (beats/min) | 155.0 ± 21.1 | 160.2 ± 19.7 | .147 |
| % heart rate achieved | 95.6 ± 14.0 | 95.6 ± 9.6 | .967 |
| Peak SBP (mm Hg) | 166.2 ± 20.7 | 165.6 ± 23.6 | .902 |
| Peak DBP (mm Hg) | 75.7 ± 17.3 | 75.8 ± 14.3 | .956 |
| Peak MBP (mm Hg) | 105.8 ± 16.2 | 105.8 ± 14.5 | .976 |
| Symptoms during exercise testing | 10 (31.3) | 252 (42.9) | .270 |
| ST segment depression ≥1 mm during exercise testing | 4 (12.5) | 93 (15.8) | .804 |
| Baseline | |||
| QT max (ms) | 391.2 ± 24.9 | 383.0 ± 30.1 | .129 |
| QT min (ms) | 363.5 ± 24.2 | 355.9 ± 28.6 | .145 |
| QTd (ms) | 27.8 ± 9.0 | 27.5 ± 9.6 | .863 |
| QTcd (ms) | 29.9 ± 10.1 | 30.1 ± 11.1 | .786 |
| Postexercise | |||
| QT max (ms) | 321.3 ± 27.5 | 310.7 ± 25.0 | .021 |
| QT min (ms) | 275.3 ± 25.8 | 274.7 ± 23.2 | .888 |
| QTd (ms) | 46.1 ± 9.6 | 36.0 ± 10.2 | <.001 |
| QTcd (ms) | 64.3 ± 14.7 | 50.8 ± 14.5 | <.001 |
SBP, systolic blood pressure; DBP, diastolic blood pressure; MBP, mean blood pressure.
Statistically significant to p < .05.
Figure 3(a) Change in QTd (ΔQTd) with exercise in patients with NSVT and without NSVT. In both groups, QTd was significantly increased postexercise when compared with baseline values (p < .001). Error bars represent mean with a 95% confidence interval. NSVT, nonsustained ventricular tachycardia. (b) Comparison of ΔQTd in patients with NSVT and without NSVT. The ΔQTd was significantly greater in those with NSVT compared with those without NSVT (p < .001). NSVT, nonsustained ventricular tachycardia; ΔQTd, postexercise QTd – baseline QTd